{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:19:31Z","timestamp":1778876371432,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08 CA270385."],"award-info":[{"award-number":["K08 CA270385."]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary aldosteronism (PA) can be treated surgically or medically depending on disease lateralization and surgical candidacy. There is a dearth of data directly comparing antihypertensive medication trajectories and costs between these strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      We performed a retrospective cohort study of patients with new PA diagnoses and adrenal vein sampling to assess antihypertensive medication outcomes and treatment costs using Optum\u2019s de-identified Clinformatics\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Data Mart Database (2004\u20132022). Patients were stratified by receipt of adrenalectomy versus medical management alone. The index time point was defined as adrenal vein sampling (AVS) for medically managed and adrenalectomy for surgically managed patients. Outcomes were assessed using regression models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 911 patients, 52% underwent adrenalectomy and 48% medical therapy. Adrenalectomy patients were younger, with higher Elixhauser scores. Antihypertensive medication use (2.9 versus 2.8,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.636) and costs did not differ at index. After 1 year, adrenalectomy patients used fewer antihypertensive medications (1.5 \u00b1 1.4) than medically managed patients (2.5\u00b11.5,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). On regression, age (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      = 0.02,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002), male sex (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      = 0.40,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), and baseline antihypertensive medications (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      = 0.43,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) were associated with higher antihypertensive medication requirement. Adrenalectomy patients were prescribed 1.11 fewer antihypertensive medications at one year (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). In the resistant hypertension subcohort, adrenalectomy reduced antihypertensive medications by 1.35 (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Adrenalectomy was associated with US $908 lower antihypertensive medication prescription costs (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and 87% lower odds of potassium supplementation (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with PA who undergo adrenalectomy demonstrate a significant reduction in antihypertensive medications compared with medically managed patients. While there is significant upfront cost to surgical intervention, reduced long-term prescription costs are realized.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19347-0","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T19:01:37Z","timestamp":1772650897000},"page":"5659-5668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fewer Pills, Lower Bills: Antihypertensive and Cost Outcomes of Adrenalectomy in Primary Aldosteronism"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6599-0397","authenticated-orcid":false,"given":"Jesse E.","family":"Passman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Owei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Brensinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taryn","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren R.","family":"Kelz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordana B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Wachtel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"5","key":"19347_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4330\/wjc.v6.i5.227","volume":"6","author":"A Aronova","year":"2014","unstructured":"Aronova A, Fahey TJ III, Zarnegar R. Management of hypertension in primary aldosteronism. World J Cardiol. 2014;6(5):227\u201333.","journal-title":"World J Cardiol."},{"issue":"5","key":"19347_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916.","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"19347_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1053\/j.ajkd.2023.01.447","volume":"82","author":"M Funes Hernandez","year":"2023","unstructured":"Funes Hernandez M, Bhalla V. Underdiagnosis of primary aldosteronism: a review of screening and detection. Am J Kidney Dis. 2023;82(3):333\u201346.","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"19347_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.mcna.2021.11.004","volume":"106","author":"H Sarathy","year":"2022","unstructured":"Sarathy H, Salman LA, Lee C, Cohen JB. Evaluation and management of secondary hypertension. Med Clin North Am. 2022;106(2):269\u201383.","journal-title":"Med Clin North Am."},{"issue":"1","key":"19347_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12902-017-0209-z","volume":"17","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Zhang M, Ke S, Liu L. Hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis. BMC Endocrine Disorders. 2017;17(1):61.","journal-title":"BMC Endocrine Disorders"},{"issue":"11","key":"19347_CR6","first-page":"e114","volume":"152","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, et al. AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(11):e114\u2013218.","journal-title":"Circulation"},{"issue":"12","key":"19347_CR7","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/ajh\/hpac079","volume":"35","author":"A Vaidya","year":"2022","unstructured":"Vaidya A, Hundemer GL, Nanba K, Parksook WW, Brown JM. Primary aldosteronism: state-of-the-art review. Am J Hypertens. 2022;35(12):967\u201388.","journal-title":"Am J Hypertens."},{"issue":"1","key":"19347_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41371-023-00875-1","volume":"38","author":"L Faconti","year":"2024","unstructured":"Faconti L, Kulkarni S, Delles C, et al. Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society. J Hum Hypertens. 2024;38(1):8\u201318.","journal-title":"J Hum Hypertens."},{"issue":"5","key":"19347_CR9","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916.","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"19347_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","volume":"157","author":"L Yip","year":"2022","unstructured":"Yip L, Duh QY, Wachtel H, et al. American Association of Endocrine Surgeons guidelines for adrenalectomy: executive summary. JAMA Surg. 2022;157(10):870\u20137.","journal-title":"JAMA Surg."},{"issue":"4","key":"19347_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/bjs.9744","volume":"102","author":"A Muth","year":"2015","unstructured":"Muth A, Ragnarsson O, Johannsson G, Wangberg B. Systematic review of surgery and outcomes in patients with primary aldosteronism. Br J Surg. 2015;102(4):307\u201317.","journal-title":"Br J Surg."},{"issue":"12","key":"19347_CR12","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/jch.12916","volume":"18","author":"JL Benham","year":"2016","unstructured":"Benham JL, Eldoma M, Khokhar B, Roberts DJ, Rabi DM, Kline GA. Proportion of patients with hypertension resolution following adrenalectomy for primary aldosteronism: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2016;18(12):1205\u201312.","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"4","key":"19347_CR13","doi-asserted-by":"publisher","first-page":"e185842","DOI":"10.1001\/jamasurg.2018.5842","volume":"154","author":"WM Vorselaars","year":"2019","unstructured":"Vorselaars WM, Nell S, Postma EL, Zarnegar R, Drake FT, Duh QY, Talutis SD, McAneny DB, McManus C, Lee JA, Grant SB. Clinical outcomes after unilateral adrenalectomy for primary aldosteronism. JAMA surgery. 2019;154(4):e185842.","journal-title":"JAMA surgery"},{"issue":"6","key":"19347_CR14","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.surg.2010.09.012","volume":"148","author":"B Reimel","year":"2010","unstructured":"Reimel B, Zanocco K, Russo MJ, Zarnegar R, Clark OH, Allendorf JD, Chabot JA, Duh QY, Lee JA, Sturgeon C. The management of aldosterone-producing adrenal adenomas\u2014Does adrenalectomy increase costs? Surgery. 2010;148(6):1178\u201385.","journal-title":"Surgery"},{"issue":"9596","key":"19347_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The lancet. 2007;370(9596):1453\u20137.","journal-title":"The lancet."},{"key":"19347_CR16","unstructured":"SAS Version 9.4 [computer program]. Cary, NC, USA: SAS Institute Inc.; 2023."},{"issue":"12","key":"19347_CR17","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1046\/j.1365-2168.2002.02261.x","volume":"89","author":"M Sywak","year":"2002","unstructured":"Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg. 2002;89(12):1587\u201393.","journal-title":"Br J Surg."},{"issue":"6","key":"19347_CR18","first-page":"621","volume":"8","author":"CC Lubitz","year":"2015","unstructured":"Lubitz CC, Economopoulos KP, Sy S, et al. Cost-effectiveness of screening for primary aldosteronism and subtype diagnosis in the resistant hypertensive patients. Circulation. 2015;8(6):621\u201330.","journal-title":"Circulation."},{"issue":"9","key":"19347_CR19","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1038\/s41440-025-02273-1","volume":"48","author":"Y Yoshida","year":"2025","unstructured":"Yoshida Y, Kinouchi K, Nagai S, et al. A systematic review to compare adrenalectomy and mineralocorticoid receptor antagonists in patients with unilateral primary aldosteronism. Hypertens Res. 2025;48(9):2368\u201375.","journal-title":"Hypertens Res."},{"issue":"2","key":"19347_CR20","doi-asserted-by":"publisher","first-page":"e230708","DOI":"10.1001\/jamanetworkopen.2023.0708","volume":"6","author":"C-T Liao","year":"2023","unstructured":"Liao C-T, Toh HS, Sun L, et al. Cost-effectiveness of intensive vs standard blood pressure control among older patients with hypertension. JAMA Netw Open. 2023;6(2):e230708\u2013e230708.","journal-title":"JAMA Netw Open."},{"issue":"8","key":"19347_CR21","volume":"18","author":"JM Penko","year":"2025","unstructured":"Penko JM, Bellows BK, Hennessy S, et al. Cost-effectiveness of hypertension treatment according to 2017 American College of Cardiology and American Heart Association guidelines. Circulation. 2025;18(8):e011872.","journal-title":"Circulation."},{"issue":"9","key":"19347_CR22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689\u201399.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"19347_CR23","doi-asserted-by":"publisher","first-page":"18935","DOI":"10.1038\/s41598-025-03912-w","volume":"15","author":"K Harirugsakul","year":"2025","unstructured":"Harirugsakul K, Suharitdumrong S, Panumatrassamee K, Ratchanon S, Usawachintachit M, Sowanthip D, Pobpan P, Sainont G, Santingamkun A. Novel predictive factors scoring model for persistent hypertension after adrenalectomy in patients with primary aldosteronism. Sci Rep. 2025;15(1):18935.","journal-title":"Sci Rep"},{"issue":"12","key":"19347_CR24","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1210\/jc.2013-2805","volume":"98","author":"P Mulatero","year":"2013","unstructured":"Mulatero P, Monticone S, Bertello C, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826\u201333.","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"19347_CR25","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","volume":"50","author":"C Catena","year":"2007","unstructured":"Catena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50(5):911\u20138.","journal-title":"Hypertension."},{"issue":"1","key":"19347_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"Catena C, Colussi G, Nadalini E, Chiuch A, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168(1):80\u20135.","journal-title":"Arch Intern Med."},{"issue":"3","key":"19347_CR27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","volume":"60","author":"M Reincke","year":"2012","unstructured":"Reincke M, Fischer E, Gerum S, et al. Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry. Hypertension. 2012;60(3):618\u201324.","journal-title":"Hypertension."},{"issue":"1","key":"19347_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","volume":"62","author":"GP Rossi","year":"2013","unstructured":"Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62(1):62\u20139.","journal-title":"Hypertension."},{"issue":"1","key":"19347_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","volume":"25","author":"G Giacchetti","year":"2007","unstructured":"Giacchetti G, Ronconi V, Turchi F, Agostinelli L, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. Journal of Hypertension. 2007;25(1):177\u201386.","journal-title":"Journal of Hypertension."},{"issue":"9","key":"19347_CR30","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1210\/jc.2006-0736","volume":"91","author":"C Catena","year":"2006","unstructured":"Catena C, Lapenna R, Baroselli S, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91(9):3457\u201363.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"19347_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/EJE-12-0631","volume":"168","author":"V Fourkiotis","year":"2013","unstructured":"Fourkiotis V, Vonend O, Diederich S, et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol. 2013;168(1):75\u201381.","journal-title":"Eur J Endocrinol."},{"issue":"5","key":"19347_CR32","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1210\/jc.2013-2180","volume":"99","author":"Y Iwakura","year":"2014","unstructured":"Iwakura Y, Morimoto R, Kudo M, et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab. 2014;99(5):1593\u20138.","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"19347_CR33","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1210\/jc.2008-1851","volume":"94","author":"M Reincke","year":"2009","unstructured":"Reincke M, Rump LC, Quinkler M, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab. 2009;94(3):869\u201375.","journal-title":"J Clin Endocrinol Metab."},{"issue":"22","key":"19347_CR34","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","volume":"295","author":"LA Sechi","year":"2006","unstructured":"Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. Jama. 2006;295(22):2638\u201345.","journal-title":"Jama"},{"issue":"4","key":"19347_CR35","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1210\/jc.2008-2245","volume":"94","author":"LA Sechi","year":"2009","unstructured":"Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab. 2009;94(4):1191\u20137.","journal-title":"J Clin Endocrinol Metab."},{"issue":"15\u201316","key":"19347_CR36","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.cca.2011.02.018","volume":"412","author":"VC Wu","year":"2011","unstructured":"Wu VC, Yang SY, Lin JW, et al. Kidney impairment in primary aldosteronism. Clin Chim Acta. 2011;412(15\u201316):1319\u201325.","journal-title":"Clin Chim Acta."},{"issue":"9","key":"19347_CR37","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1097\/HJH.0b013e3283495cbb","volume":"29","author":"VC Wu","year":"2011","unstructured":"Wu VC, Kuo CC, Wang SM, et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens. 2011;29(9):1778\u201386.","journal-title":"J Hypertens."},{"issue":"3","key":"19347_CR38","doi-asserted-by":"publisher","first-page":"e1280","DOI":"10.1210\/clinem\/dgad654","volume":"109","author":"S Samnani","year":"2024","unstructured":"Samnani S, Cenzer I, Kline GA, et al. Time to benefit of surgery vs targeted medical therapy for patients with primary aldosteronism: a meta-analysis. J Clin Endocrinol Metab. 2024;109(3):e1280\u20139.","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"19347_CR39","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1210\/jc.2011-0138","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab. 2011;96(9):2904\u201311.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"19347_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/jc.2017-01442","volume":"103","author":"M Velema","year":"2018","unstructured":"Velema M, Dekkers T, Hermus A, et al. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment. J Clin Endocrinol Metab. 2018;103(1):16\u201324.","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"19347_CR41","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.jpsychires.2012.08.025","volume":"46","author":"HE Kunzel","year":"2012","unstructured":"Kunzel HE, Apostolopoulou K, Pallauf A, et al. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. J Psychiatr Res. 2012;46(12):1650\u20134.","journal-title":"J Psychiatr Res."},{"issue":"1","key":"19347_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3109\/15622975.2012.665480","volume":"15","author":"K Apostolopoulou","year":"2014","unstructured":"Apostolopoulou K, Kunzel HE, Gerum S, et al. Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: a cross-sectional study. World J Biol Psychiatry. 2014;15(1):26\u201335.","journal-title":"World J Biol Psychiatry."},{"issue":"7","key":"19347_CR43","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1245\/s10434-013-2871-3","volume":"20","author":"GA Kline","year":"2013","unstructured":"Kline GA, Pasieka JL, Harvey A, So B, Dias VC. Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes. Ann Surg Oncol. 2013;20(7):2274\u20138.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19347-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19347-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19347-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:02:17Z","timestamp":1778875337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19347-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["19347"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19347-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no disclosure to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}